‘Breakthrough Therapy Designation’ to Novel Schizophrenia Drug- SEP-363856 2 years ago Newsdesk U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for SEP-363856, a novel…
FDA Approves Brexanolone (ZULRESSO) -First Treatment for Post-Partum Depression 2 years ago Newsdesk US FDA Approves Brexanolone (ZULRESSO) -First Treatment for Post-Partum Depression The U.S. Food and Drug…
